The Government of India is presently engaged in the implementation of a prevention and control programme for two major forms of haemoglobinopathies, thalassaemia major and sickle cell disease, with guidelines for their prevention and management formulated under the National Health Mission. Based on projections for the population up to the year 2026, the annual blood requirement for treatment will increase to 9.24 million units, together with an 86% increase in budgetary requirements which then would account for over 19% of the current National Health Budget. To avert a public health crisis there is an urgent need to fully implement the prevention programme for haemoglobinopathies.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Alswaidi FM, Memish ZA, O’Brian SJ, Al-Hamdan NA, Al-Enzy FM, Alhayani OA, Al-Wadey AM (2012) At-risk marriages after compulsory premarital testing and counseling for β-thalassemia and sickle cell disease in Saudi Arabia. J Gen Counsel 21:243–255
Amato A, Cappabianca MP, Lerone M, Colosimo A, Grisanti P, Ponzini D, Di Biagio P, Perri M, Gianni D, Rinaldi S, Piscitelli R (2014) Carrier screening for inherited haemoglobin disorders among secondary school students and young adults in Latium, Italy. J Commun Genet 5:265–268
Basu A, Sarkar-Roy N, Majumder PP (2016) Genomic reconstruction of the history of extant populations of India reveals five distinct ancestral components and a complex structure. Proc Natl Acad Sci U S A 113:1594–1599
Bittles AH (2002) Endogamy, consanguinity and community genetics. J Genet 81:44–50
Bittles AH (2012) Consanguinity in context. Cambridge University Press, Cambridge
Black ML, Sinha S, Agarwal S, Colah R, Das R, Bellgard M, Bittles AH (2010) A descriptive profile of β-thalassaemia mutations in India, Pakistan and Sri Lanka. J Commun Genet 1:149–157
Bozkurt G (2007) Results from the north Cyprus thalassemia prevention program. Hemoglobin 31:257–264
Census of India (2011) Figures at a glance. http://censusindia.gov.in/2011-prov-results/indiaatglance.html
Chandy M (2008) Developing a national programme for India. In: Ghosh K, Colah R (eds) Control and Management of Thalassemia and other Hemoglobinopathies in the Indian Subcontinent_ Synoptic Views. National Institute of Immunohaematology, Mumbai
Colah RB, Gorakshakar A (2014) Control of thalassemia in India. Thal Reports 4(s1):1955. https://doi.org/10.4081/thal.2014.s1.1955
Colah R, Mukherjee M, Ghosh K (2014) Sickle cell disease in India. Curr Opin Hematol 21:215–223
Colah RB, Mehta P, Mukherjee MB (2018) Newborn screening for sickle cell disease: Indian experience. Int J Neonatal Screen 4:31. https://doi.org/10.3390/ijns4040031
Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB (2010) Carrier screening for Beta-thalassaemia: a review of international practice. Eur J Hum Genet 18:1077–1083
Educational Statistics at a Glance (2016) Department of School Education and Literacy, Ministry of Human Resource Development. Government of India, New Delhi
Giordano PC (2009) Prospective and retrospective primary prevention of hemoglobinopathies in multiethnic societies. Clin Biochem 42:1757–1766. https://doi.org/10.1016/j.clinbiochem.2009.06.027
Hockham C, Bhatt S, Colah R, Mukherjee MB, Penman BS, Gupta S, Piel F (2018) The spatial epidemiology of sickle-cell anaemia in India. Sci Rep 8:17685. https://doi.org/10.1038/s41598-018-36077-w
India State-Level Disease Burden Initiative Collaborators (2017) Nations within a nation: variations in epidemiological transition across the states of India, 1990–2026 in the Global Burden of Disease Study. Lancet 390:2437–2460
Lau EHY, He X-Q, Lee C-K, Wu JT (2013) Predicting future blood demand from thalassemia major patients in Hong Kong. PLoS One 8(12):e81846. https://doi.org/10.1371/journal.pone.0081846
Loukopoulos D (2011) Haemoglobinopathies in Greece: prevention programme over the past 35 years. Ind J Med Res 134:572–576
Miri M, Tabrizi Namini M, Hadipour Dehshal M, Sadeghian Varnosfaderani F, Ahmadvand A, Yousefi Darestani S, Manshadi M (2013) Thalassemia in Iran in last twenty years: the carrier rates and the births trend. Iran J Blood Cancer 6:11–18
Mitchell JJ, Capua A, Clow C, Scriver CR (1996) Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and β-thalassemia disease carriers in high schools. Am J Hum Genet 59:793–798
Modell B (ed) (1989) Guidelines for control of haemoglobin disorders. WHO Working Group on Haemoglobinopathies. WHO_HDP_HB_GL_94.1.pdf
NACO (2016) Blood Transfusion Services (BTS) data for FY 2015–2016. National AIDS Control Organization, Government of India http://naco.gov.in/sites/default/files/BTS%20Data%202015-16.pdf
NACO (2017) Blood Transfusion Services (BTS) data for FY 2016–2017. National AIDS Control Organization, Government of India http://naco.gov.in/blood-transfusion-services-publications
Nakatsuka N, Moorjani P, Rai N, Sarkar B, Tandon A, Patterson N, Bhavani GS, Girisha KM, Mustak MS, Srinivasan S, Kaushik A, Vahab SA, Jagadeesh SM, Satyamoorthy K, Singh L, Reich D, Thangaraj K (2017) The promise of discovering population-specific disease-associated genes in South Asia. Nat Genet 49:1403–1407
National Health Mission Guidelines on Hemoglobinopathies in India (2016) Prevention and Control of Hemoglobinopathies in India. National Health Mission, Ministry of Health & Family Welfare, Government of India http://nhm.gov.in/images/pdf/programmes/RBSK/Resource_Documents/Guidelines_on_Hemoglobinopathies_in%20India.pdf
Old J, Angastiniotis M, Eleftheriou A, Hartveld C, Petrou M, Traeger-Synodinos J (2013) Prevention of thalassaemias and other haemoglobin disorders Volume 1: principles, 2nd edn. Thalassaemia International Federation, Cyprus
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI (2013) Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 381:142–151
Population Projections for India and States 2001-2026 (2006) Report of the technical group on population projections constituted by the National Commission on Population, Registrar General & Census Commissioner, India. Office of the Registrar General & Census Commissioner, New Delhi
Rees DC, Brouse VAM (2016) Sickle cell disease: status with particular reference to India (Editorial). Ind J Med Res 143:675–677
Registrar General of India (2017) Sample Registration System, Vital Statistics Division, Office of the Registrar General of India, New Delhi. SRS Bulletin 51(1):1 http://censusindia.gov.in/vital_statistics/SRS_Bulletins/Bulletins.html
Sharma S, Seth B, Jawade P, Ingale M, Setia MS (2017) Quality of life in children with thalassemia and their caregivers in India. Ind J Pediatr 84:188–194
Sinha S, Black ML, Agarwal S, Colah R, Das R, Ryan K, Bellgard M, Bittles AH (2009) Profiling β-thalassaemia mutations in India at state and regional levels: implications for genetic education, screening and counseling programmes. HUGO J 3:51–62
Sinha S, Black ML, Agarwal S, Das R, Bittles AH, Bellgard M (2011) ThalInd, a β-thalassaemia and hemoglobinopathies database for India: defining a model country-specific and disease-centric bioinformatics resource. Hum Mutat 32:887–893
SRS Bulletins, Sample Registration System, Registrar General, India. Published by office of the Registrar General, India, Ministry of Home Affairs, Government of India. http://censusindia.gov.in/vital_statistics/SRS_Bulletins/Bulletins.html
Trehan A, Sharma N, Das R, Bansl D, Marwaha RK (2015) Clinico-investigational and demographic profile of children with thalassemia major. Ind J Hematol Blood Transfus 31:121–126
World Population Data Sheet (2018) Population Reference Bureau, Washington DC. http://www.prb.org/wp-content/uploads/2018/08/2018_WPDS.pdf
World Population Datasheet (2016) Population Reference Bureau, Washington DC. http://www.prb.org/pdf16/prb- wpds2016-web-2016.pdf
Permission for the use of anonymised data on blood requirements of thalassaemia patients was provided by each of the four collaborating centres.
Conflict of interest
In 2017, AHB acted as consultant on consanguinity for Merck, Sharp and Dohme. SS, TS and RC have nothing to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Sinha, S., Seth, T., Colah, R.B. et al. Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017–2026. J Community Genet 11, 39–45 (2020). https://doi.org/10.1007/s12687-019-00410-1
- Sickle cell disease
- Transfusion needs
- Health budget
- Public health